EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)

Bayer1,180 enrolled

Overview

In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels (metastatic castration-resistant prostate cancer, mCRPC). In addition researchers want to identify the factors which may contribute to survival over a long period of time in those patients. Radium-223 (Ra-223) is an alpha particle-emitting radioactive agent approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).

Study Type

OBSERVATIONAL

Enrollment

1,180

Conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

Radium-223 dichloride (Xofigo, BAY88-8223)DRUG

Receiving Ra-223 either alone or in combination with other cancer therapies at any time after diagnosis of mCRPC

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria * Adult patients with documented diagnosis of mCRPC (≥18 years at diagnosis), and * Received Ra-223 as one of the therapies between Jan 1, 2013 and Jun 31, 2019 after diagnosis of mCRPC Exclusion criteria \- Patients involved in clinical trials

Outcomes

Primary Outcomes

Overall survival from initiation of Ra-223

Time frame: Retrospective analysis from Jan 2013 to Dec 2019

Secondary Outcomes

Percentage of Prostate Specific Antigen (PSA) (unit: µg/L) response after Ra-223

PSA response will be defined ≥ 50% reduction in baseline PSA level after initiation of Ra-223